Skip to main content


Log in

Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript



Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients’ quality of life is significantly affected by more frequent angina events, which increase the risk of revascularization.


To assess the cost-utility of ranolazine versus placebo as an add-on therapy for the symptomatic treatment of patients with chronic angina pectoris in Spain.


A decision tree model with 1-year time horizon was designed. Transition probabilities and utility values for different angina frequencies were obtained from the literature. Costs were obtained from Spanish official DRGs for patients with chronic angina pectoris. We calculated the incremental cost-utility ratio of using ranolazine compared with a placebo. Sensitivity analyses, by means of Monte Carlo simulations, were performed. Acceptability curves and expected value of perfect information were calculated.


The incremental cost-utility ratio was €8,455 per quality-adjusted life-year (QALY) per patient in Spain. Sensitivity analyses showed that if the decision makers’ willingness to pay is €15,000 per QALY, the treatment with ranolazine will be cost effective at a 95 % level of confidence. The incremental cost-utility ratio is particularly sensitive to changes in utility values of those non-hospitalized patients with mild or moderate angina frequency.


Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others


  1. Lopez-Sendon, J.: Chronic stable angina guidelines: is there an emerging international consensus? Br J Cardiol 19(Suppl. 2), S2–S11 (2012)

    Google Scholar 

  2. Boden, W.E.: Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med 356(15), 1503–1516 (2007)

    Article  CAS  PubMed  Google Scholar 

  3. Keating, G.M.: Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs 73(1), 55–73 (2013)

    Article  CAS  PubMed  Google Scholar 

  4. Brown, N., Melville, M., Gray, D., Young, T., Munro, J., Skene, A.M., et al.: Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart 81(4), 352–358 (1999)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Brorsson, B., Bernstein, S.J., Brook, R.H., Werko, L.: Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 87(2), 140–145 (2002)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Arnold, S.V., Morrow, D.A., Lei, Y., Cohen, D.J., Mahoney, E.M., Braunwald, E., et al.: Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2(4), 344–353 (2009)

    Article  PubMed  Google Scholar 

  7. Beltrame, J.F., Weekes, A.J., Morgan, C., Tavella, R., Spertus, J.A.: The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) Study. Arch. Intern. Med 169(16), 1491–1499 (2009)

    Article  PubMed  Google Scholar 

  8. Maddox, T.M., Reid, K.J., Spertus, J.A., Mittleman, M., Krumholz, H.M., Parashar, S., et al.: Angina at 1 year after myocardial infarction: prevalence and associated findings. Arch. Intern. Med 168(12), 1310–1316 (2008)

    Article  PubMed  Google Scholar 

  9. Kosiborod, M., Arnold, S.V., Spertus, J.A., McGuire, D.K., Li, Y., Yue, P., et al.: Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina). J. Am. Coll. Cardiol 61(20), 2038–2045 (2013)

    Article  CAS  PubMed  Google Scholar 

  10. EMEA. EPAR for Ranexa. Available at: Updated on Sep 14th, 2009

  11. Alonso, J.J., Bueno, H.: Angina de pecho estable. Trascendencia clínica en la era de la intervención, limitaciones y avances actuales de su terapia farmacológica. Rev. Esp. Cardiol 7(Supl D), 9–18 (2007)

    Google Scholar 

  12. Chaitman, B., Skettino, S., Parker, J., Hanley, P., Meluzin, J., Kuch, J., et al.: Anti-ischemia effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43(8), 1375–1382 (2004)

    Article  CAS  PubMed  Google Scholar 

  13. Chaitman, B., Pepine, C., Parker, J., Skopal, J., Chumakova, G., Kuch, J., et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 291(3), 309–316 (2004)

    Article  CAS  PubMed  Google Scholar 

  14. Stone, P.H.G.N., Blokhin, A., et al.: Anti-anginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J. Am. Coll. Cardiol 48, 566–575 (2006)

    Article  CAS  PubMed  Google Scholar 

  15. Arnold, S.V., Morrow, D.A., Wang, K., Lei, Y., Mahoney, E.M., Scirica, B.M., Braunwald, E., Cohen, D.J., MERLIN-TIMI 36 Investigators: Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 1(2), 107–115 (2008). Epub 2008 Nov 5

    Article  PubMed  Google Scholar 

  16. Morrow, D.A., Scirica, B.M., Karwatowska-Prokopczuk, E.: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297(16), 1775–1783 (2007)

    Article  CAS  PubMed  Google Scholar 

  17. Shaw, J.W., Johnson, J.A., Coons, S.J.: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43(3), 203–220 (2005)

    Article  PubMed  Google Scholar 

  18. Sossalla, S., Maier, L.S.: Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 133(3), 311–323 (2012)

    Article  CAS  PubMed  Google Scholar 

  19. Lucioni, C., Mazzi, S.: Una valutazione economica di ranolazina add-on nel trattamento dell′angina stabile cronica. Pharmaco Econ Italian Res Art 11(3), 141–152 (2009)

    Article  Google Scholar 

  20. Karwatowska-Prokopczuk, E., Wang, W., Cheng, M.L., Zeng, D., Schwartz, P.J., Belardinelli, L.: The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace 15(3), 429–436 (2013)

    Article  PubMed  Google Scholar 

  21. Etemad, L., McCollam, P.: Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 11, 300–306 (2005)

    PubMed  Google Scholar 

  22. Spertus, J.A., Winder, J.A., Dewhurst, T.A., et al.: Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 25, 333–341 (1995)

    Article  CAS  PubMed  Google Scholar 

  23. Fox, K., Garcia, M.A., Ardissino, D., Buszman, P., Camici, P.G., Crea, F., et al.: Guidelines on the management of stable angina pectoris. Executive summary. Rev Esp Cardiol 59(9), 919–970 (2006)

    Article  PubMed  Google Scholar 

  24. Consejo General de Colegios Oficiales de Farmacéuticos (2010) Base de datos del medicamento. Disponible en: (consultado abril 2010)

  25. Ministerio de Sanidad y Política Social (2010) Información sobre los productos incluidos en la prestación farmacéutica del SNS (dispensables a través de oficinas de farmacia). Disponible en: (consultado abril 2010)

  26. Daly, C., Clemens, F., Lopez Sendon, J., Tavazzi, L., Boersma, E., Danchin, N., et al.: The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 26, 1011–1022 (2005)

    Article  PubMed  Google Scholar 

  27. Oblikue Consulting (2010) eSalud: Base de datos de información económica del sistema sanitario. Disponible en (consultado junio 2010)

  28. Ministerio de Sanidad y Consumo (2010) Explotación del CMBD 2008. (consultado en junio de 2010)

  29. Longworth, I., Bluxton, M., Sculpher, M.: Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ 6, 347–353 (2005)

    Article  PubMed  Google Scholar 

  30. Griffin, S., Barber, J., Manca, A.: Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. British Med J 334, 624–628 (2007)

    Article  CAS  Google Scholar 

  31. Briggs, A., Sculpher, M., Claxton, K.: Decision modelling for health economics. Oxford University Press, Oxford (2006)

    Google Scholar 

  32. Claxton,  K.: Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 8(3), 269–274 (1999)

    Article  CAS  PubMed  Google Scholar 

  33. Sacristán, J., Oliva, J., Del Llano, J., Prieto, L., Pinto, J.: What is an efficient health technology in Spain? Gac Sanit 16(4), 334–343 (2002)

    Article  PubMed  Google Scholar 

Download references


The authors thank Antonio Zapata, Elena Saura, and Mónica Casañas from Grupo Menarini Spain, for the help provided for the study. The study was financed by Grupo Menarini, Spain.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Juan Manuel Ramos-Goñi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hidalgo-Vega, Á., Ramos-Goñi, J.M. & Villoro, R. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Eur J Health Econ 15, 917–925 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


JEL Classification